A Phase 3 interventional study of Delgocitinib and Toctino in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 102 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.
Among the 13 studies in Eczema by LEO Pharma, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 3, and was the 9th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:
LEO Pharma · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 513 is above the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 178 across the 12 interventional studies, 1,000 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Eczema by LEO Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.
The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.
Main inclusion criteria:
Main exclusion criteria:
Any disorder which is not stable and could:
Treatment with any marketed biological therapy or biologic agents:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice-daily topical application for up to 24 weeks
Drug: Delgocitinib
1 capsule per day for up to 24 weeks
Drug: Toctino
Cream for topical application 20 mg/g
1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Change in HECSI Score From Baseline to Week 12
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
Time frame: 12 weeks
HECSI-90 at Week 12
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
Time frame: 12 weeks
IGA-CHE TS at Week 12.
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
Time frame: 12 weeks
Change in HESD Itch Score (Weekly Average) From Baseline to Week 12
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.
Time frame: 12 weeks
Change in HESD Pain Score (Weekly Average) From Baseline to Week 12.
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.
Time frame: 12 weeks
AUC of HECSI-90 From Baseline up to Week 24
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.
Time frame: 24 weeks
AUC of Change From Baseline in DLQI Score up to Week 24
The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.
Time frame: 24 weeks
Change in HECSI Score From Baseline to Week 24
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
Time frame: 24 weeks
Number of Treatment-emergent AEs From Baseline up to Week 26
An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
Time frame: 26 weeks
Number of Treatment-emergent SAEs From Baseline up to Week 26
A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
Time frame: 26 weeks
Number of AEs Leading to IMP Discontinuation up to Week 24
The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).
Time frame: 24 weeks
The trial enrolled adult participants with severe CHE and with a documented inadequate response to treatment with TCS or for whom TCS were documented to be otherwise medically inadvisable.
| Milestone | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Started | 254 | 259 |
| Completed | 219 | 154 |
| Not completed | 35 | 105 |
| Withdrew: Adverse event | 2 | 24 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Lack of efficacy | 8 | 26 |
| Withdrew: Withdrawal by subject | 15 | 33 |
| Withdrew: Various reasons | 3 | 9 |
| Withdrew: Not exposed to imp | 1 | 12 |
| Withdrew: Discontinuation of imp, related to covid-19 | 1 | 0 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
| score on a scale | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Change in HECSI Score From Baseline to Week 12 | -67.6 ± 3.37 | -51.5 ± 3.36 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
| Participants | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| HECSI-90 at Week 12 | 96 | 65 |
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
| Participants | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| IGA-CHE TS at Week 12. | 68 | 42 |
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.
| score on a scale | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Change in HESD Itch Score (Weekly Average) From Baseline to Week 12 | -3.0 ± 0.22 | -2.4 ± 0.21 |
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.
| score on a scale | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Change in HESD Pain Score (Weekly Average) From Baseline to Week 12. | -2.9 ± 0.23 | -2.3 ± 0.23 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.
| days with 90% reduction in HECSI score | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| AUC of HECSI-90 From Baseline up to Week 24 | 51.1 ± 4.11 | 43.5 ± 4.22 |
The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.
| days * DLQI score reduction | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| AUC of Change From Baseline in DLQI Score up to Week 24 | 1124.7 ± 61.37 | 790.7 ± 62.67 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
| score on a scale | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Change in HECSI Score From Baseline to Week 24 | -69.6 ± 3.78 | -45.1 ± 3.77 |
An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
| events | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Number of Treatment-emergent AEs From Baseline up to Week 26 | 280 | 620 |
A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
| events | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Number of Treatment-emergent SAEs From Baseline up to Week 26 | 5 | 12 |
The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).
| events | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Number of AEs Leading to IMP Discontinuation up to Week 24 | 4 | 44 |
Collected over From baseline to Week 26. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | 0/253 (0%) | 5/253 (2%) | 58/253 (22.9%) |
| Alitretinoin Capsules 30 mg Per Capsule | 0/247 (0%) | 12/247 (4.9%) | 143/247 (57.9%) |
| Event | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| Gastrointestinal inflammationGastrointestinal disorders | 0/253 | 1/247 |
| Deep vein thrombosis postoperativeInjury, poisoning and procedural complications | 0/253 | 1/247 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/253 | 1/247 |
| International normalised ratio increasedInvestigations | 0/253 | 1/247 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/253 | 1/247 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/253 | 1/247 |
| Benign salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/253 | 1/247 |
| HeadacheNervous system disorders | 0/253 | 1/247 |
| ProstatitisReproductive system and breast disorders | 0/253 | 1/247 |
| Mediastinal cystRespiratory, thoracic and mediastinal disorders | 0/253 | 1/247 |
| Event | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule |
|---|---|---|
| HeadacheNervous system disorders | 10/253 | 79/247 |
| NasopharyngitisInfections and infestations | 30/253 | 34/247 |
| NauseaGastrointestinal disorders | 1/253 | 14/247 |
| Urinary tract infectionInfections and infestations | 1/253 | 10/247 |
| COVID-19Infections and infestations | 5/253 | 9/247 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/253 | 9/247 |
| Dry skinSkin and subcutaneous tissue disorders | 3/253 | 9/247 |
| ErythemaSkin and subcutaneous tissue disorders | 1/253 | 9/247 |
| Lip dryGastrointestinal disorders | 0/253 | 8/247 |
| Upper respiratory tract infectionInfections and infestations | 6/253 | 8/247 |
| Age, Categorical(Participants) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 238 | 233 | 471 |
| >=65 years | 16 | 26 | 42 |
| Age, Continuous(years) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| Mean | 45.4 ± 13.78 | 44.0 ± 14.56 | 44.7 ± 14.18 |
| Sex: Female, Male(Participants) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| Female | 167 | 167 | 334 |
| Male | 87 | 92 | 179 |
| Ethnicity (NIH/OMB)(Participants) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 14 | 36 |
| Not Hispanic or Latino | 226 | 241 | 467 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 9 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 5 |
| White | 237 | 240 | 477 |
| More than one race | 1 | 6 | 7 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| Canada | 25 | 29 | 54 |
| Austria | 2 | 3 | 5 |
| Norway | 1 | 1 | 2 |
| Poland | 89 | 91 | 180 |
| Italy | 13 | 9 | 22 |
| United Kingdom | 2 | 4 | 6 |
| Slovakia | 9 | 5 | 14 |
| France | 14 | 16 | 30 |
| Germany | 63 | 73 | 136 |
| Spain | 36 | 28 | 64 |
Showing the first 100 of 102 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Nov 2023, 16 months.
Results were first posted in Mar 2025, 1 year 4 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib